FDA Approves Fezolinetant for Moderate to Severe Hot Flashes in Menopause
Announced on May 12, 2023, the FDA's approval of fezolinetant (Veozah) marks their first approval for an NK3 receptor antagonist for the treatment of vasomotor symptoms of menopause.
Read More